19 citations,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
16 citations,
January 2019 in “Pharmaceutical biology” Lespedeza cuneata extract may help treat enlarged prostate.
16 citations,
October 2007 in “Andrologia” DHT is a strong androgen that may pose less risk to the prostate compared to testosterone.
16 citations,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
16 citations,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
16 citations,
September 1964 in “The journal of investigative dermatology/Journal of investigative dermatology” New compounds can block testosterone effects in rats and might help treat conditions like prostate cancer and acne.
15 citations,
January 2009 in “International Journal of Andrology” Liquorice may reduce testosterone and affect male reproductive organs, potentially helping treat conditions like prostate cancer.
15 citations,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
14 citations,
January 2020 in “Biomaterials Science” Created microspheres show potential for safe and effective use in prostate artery embolization.
14 citations,
November 2008 in “Expert opinion on drug metabolism & toxicology” Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
14 citations,
February 1994 in “Tetrahedron Letters” Adding cerium(III) chloride to Grignard reagents improves the making of compounds that could treat prostate issues and hair loss.
13 citations,
February 2022 in “JAMA Dermatology” Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.
11 citations,
September 2021 in “Journal of molecular endocrinology” ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.
11 citations,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
8 citations,
December 2011 in “Journal of Medicinal Food” D-004 may be a natural alternative to finasteride for treating enlarged prostate and male baldness.
![Synthesis, Biological Evaluation, and Molecular Docking of 4-Amino-2H-benzo[h]chromen-2-one Analogs Containing the Piperazine Moiety](/images/research/2ecf4eed-7dbe-4f1a-83db-739625546cdd/small/31808.jpg)
7 citations,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
6 citations,
January 2020 in “The Aging Male” Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.
6 citations,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.
5 citations,
January 2018 in “Interdisciplinary sciences: computational life sciences” Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.
5 citations,
June 2015 in “Chinese journal of natural medicines/Zhongguo tianran yaowu/Chinese Journal of Natural Medicines” Tripterygium wilfordii multiglycoside effectively reduced prostate enlargement in rats without harmful effects.
5 citations,
November 2012 in “The Journal of Urology” Early hair loss may indicate future prostate issues.
5 citations,
January 2010 in “Acta Chirurgica Iugoslavica” Higher urethral PSA levels after prostate removal may be linked to more scalp hair loss and more PSA in urethral glands.
4 citations,
June 2017 in “Endocrine Reviews” Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.
4 citations,
April 2020 in “Reports of Practical Oncology & Radiotherapy” Prostate cancer patients need early psychological and sexual support during radiotherapy to improve their quality of life.
Higher free testosterone levels can increase bone density and decrease body fat but may raise the risk of prostate cancer, hair loss, and benign prostate enlargement.
4 citations,
March 2017 in “Al-Mi’galaẗ al-sa'udiyaẗ lī-ulum al-ḥayaẗ” Leonuri Herba alkaloids may help treat hormone-induced enlarged prostate in rats.
4 citations,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
3 citations,
January 2008 in “Endocrine journal” A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.
3 citations,
May 2003 in “BJUI” Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.
3 citations,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.